These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16565629)

  • 1. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes.
    Cantrell CR; Eaddy MT; Shah MB; Regan TS; Sokol MC
    Med Care; 2006 Apr; 44(4):300-3. PubMed ID: 16565629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
    Stein MB; Cantrell CR; Sokol MC; Eaddy MT; Shah MB
    Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
    Sheehan DV; Eaddy MT; Shah MB; Mauch RP
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
    Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
    Wade RL; Kindermann SL; Hou Q; Thase ME
    J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
    Panzer PE; Regan TS; Chiao E; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
    Sheehan DV; Eaddy M; Sarnes M; Vishalpura T; Regan T
    J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
    Crown WH; Treglia M; Meneades L; White A
    Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.
    Eaddy MT; Druss BG; Sarnes MW; Regan TS; Frankum LE
    J Manag Care Pharm; 2005 Mar; 11(2):145-50. PubMed ID: 15766321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
    Endicott J; McLaughlin TP; Grudzinski AN
    J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.
    Wan GJ; Crown WH; Berndt ER; Finkelstein SN; Ling D
    Manag Care Interface; 2002 Jun; 15(6):24-30. PubMed ID: 12087603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression.
    Donohue JM; Berndt ER; Rosenthal M; Epstein AM; Frank RG
    Med Care; 2004 Dec; 42(12):1176-85. PubMed ID: 15550797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders.
    Keene MS; Eaddy MT; Nelson WW; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S362-9. PubMed ID: 16236018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antidepressant drug adherence on comorbid medication use and resource utilization.
    Katon W; Cantrell CR; Sokol MC; Chiao E; Gdovin JM
    Arch Intern Med; 2005 Nov; 165(21):2497-503. PubMed ID: 16314547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Course of antidepressant treatment with tricyclic versus selective serotonin reuptake inhibitor agents: a comparison in managed care and fee-for-service environments.
    Fairman KA; Teitelbaum F; Drevets WC; Engquist G; Kreisman JJ; Norusis MJ
    Am J Manag Care; 1997 Mar; 3(3):453-65. PubMed ID: 10169521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the use of SSRIs reduce medical care utilization and expenditures?
    Chung S
    J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
    Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
    Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.